<DOC>
	<DOCNO>NCT01193595</DOCNO>
	<brief_summary>Primary Objective : - To determine maximum administer dose ( MAD ) maximum tolerate dose ( MTD ) ombrabulin combination best tolerate dose bevacizumab base incidence relate Dose Limiting Toxicities ( DLTs ) . Secondary Objectives : - To assess overall safety profile combination - To characterize pharmacokinetic ( PK ) profile ombrabulin bevacizumab give combination - To evaluate preliminary evidence anti-tumor activity - To assess pharmacodynamic effect use ( Dynamic Contrast Enhanced Ultra-Sound ) DCE-US , measure biomarkers</brief_summary>
	<brief_title>Dose-escalation , Safety , Pharmacokinetics Study AVE8062 Combined With Bevacizumab Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The duration study patient include 28-day screening phase , 21-day study treatment cycle , end treatment visit follow-up period . Each patient participate one dose group receive AVE8062 bevacizumab every 3 week disease progression unacceptable toxicity , withdrawal consent Investigator 's decision .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically proven solid malignant tumor first diagnosis exception squamous non small cell lung cancer ( NSCLC ) . Advanced neoplastic disease ( i.e . metastatic locally unresectable advanced disease ) Presence one measurable lesion baseline MTD expand cohort Exclusion criterion : ECOG ( Eastern cooperativeOncology Group ) performance status &gt; 1 Concurrent treatment anticancer therapy Pericardial effusion require intervention ( drainage ) History brain metastasis , spinal cord compression carcinomatous meningitis new evidence brain metastasis screening Computed tomography ( CT ) Magnetic resonance imaging ( MRI ) scan Diagnosis squamous Non Squamous Cell Lung Cancer ( NSCLC ) mix cell type predominant squamocellular histology Hormone sensitive prostate cancer Abdominal Radiotherapy Major surgery within last month study enrollment surgical wound fully heal study enrollment High cumulative dos anthracycline Inadequate organ function Inadequate hematology function poor bone marrow reserve Any follow within 6 month prior study enrollment : peptic ulcer disease , erosive oesophagitis gastritis , infectious inflammatory bowel disease diverticulitis Any history underlying cardiac condition may increase risk associate study participation administration investigational product , may interfere interpretation result . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>